Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating the amount of computation done by a brain using population neural activity.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Luminescent heparin-functionalized carbon dots with potential applications in nanoparticle-protein interactions and cell imaging.

Scientific reports·2026
Same author

Marine-Derived Dual BTK-FGFR Inhibitors: Pioneering a New Era of Precision Oncology Therapeutics.

Anti-cancer agents in medicinal chemistry·2026
Same author

Antidiabetic effects of <i>Tipuana tipu</i> leaves: in silico docking and experimental study in streptozotocin-induced diabetic rats.

In silico pharmacology·2026
Same author

Deciphering the multi-organ anti-fibrotic mechanisms of pirfenidone and nintedanib via network pharmacology.

Personalized medicine·2026
Same author

Novel class of population mean estimators based on robust regression methods.

Scientific reports·2026

Related Experiment Video

Updated: Jul 20, 2026

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
09:18

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

Published on: June 2, 2016

Telomerase targeted anticancer bioactive prodrug by antisense-based approach.

Neha Kapoor1, Anuj Kumar Sharma, Vishnu Dwivedi

  • 1Centre for Biotechnology, University of Allahabad, Allahabad, India.

Cancer Letters
|September 5, 2006
PubMed
Summary

A novel DNA-curcumin conjugate targets telomerase, acting as a prodrug to inhibit cancer cell growth. This antisense mechanism shows promise for antitumor therapies.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Experiment Videos

Last Updated: Jul 20, 2026

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
09:18

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

Published on: June 2, 2016

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Area of Science:

  • Molecular Biology
  • Medicinal Chemistry
  • Cancer Research

Background:

  • Human telomerase is a key target for cancer therapy due to its role in cell immortalization.
  • Curcumin, a turmeric component, exhibits antitumor properties but has limited bioavailability.
  • Oligonucleotides can be designed to target specific genetic sequences, like telomerase RNA.

Purpose of the Study:

  • To synthesize and characterize a novel DNA-curcumin conjugate for targeted cancer therapy.
  • To investigate the prodrug potential and antisense mechanism of the conjugate.
  • To evaluate the effect of the conjugate on cancer cell growth.

Main Methods:

  • Synthesis of an 11-mer deoxyoligonucleotide linked to a tetraglycine curcumin conjugate.
  • Transfection of the conjugate into KB and HeLa cancer cell lines.
  • Assessment of cell growth inhibition and mechanism of action.

Main Results:

  • The DNA-curcumin-tetraglycine conjugate was successfully synthesized and transfected into cancer cells.
  • The conjugate demonstrated an effect on cell growth, particularly in KB cells.
  • The molecule functions as a prodrug, utilizing an antisense mechanism to target telomerase.

Conclusions:

  • The developed DNA-curcumin conjugate represents a promising targeted prodrug approach for cancer therapy.
  • Antisense targeting of telomerase with curcumin conjugates warrants further investigation for antitumor drug development.
  • This strategy combines the specificity of oligonucleotide targeting with the therapeutic potential of curcumin.